ClinicalTrials.gg
RecruitingNCT06378242Updated Jul 11, 2024

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

A Phase 1/2 interventional study of Disitamab Vedotin for injection in High-risk Non-muscle Invasive Bladder Cancer, sponsored by RemeGen Co., Ltd.. Recruiting at 6 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by RemeGen Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China — 40 open to participants now, 44 under way, 10 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · China.

Planned enrollment
41st of 47
24 · median 114
Started
2024
with 11 others
Phase 1/2
8 of 50
7 open now
Primary completion
2029-03
later than 35 of 43 live
Registered
24th of 50
by date
Lead sponsor
2 of 50
RemeGen Co., Ltd.

Among the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, this one is the 41st largest by planned enrollment of the 47 interventional ones that give a count, is one of 12 that started in 2024, is one of 8 in phase 1/2, reaches primary completion later than 35 of the 43 other live ones, and was the 24th registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

40 of the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of intravesical instiliations of Disitamab Vedotin in patients with high-risk non-muscular invasive bladder cancer (NMIBC) that express HER2

Read the detailed description

This is a single-arm, multicenter phase I/II clinical study to evaluate the safety, efficacy, and pharmacokinetics of intravesical instiliations of Disitamab Vedotin in patients with high-risk non-muscular invasive bladder cancer (NMIBC) that express HER2.

03

Conditions studied

  • High-risk Non-muscle Invasive Bladder Cancer

Keywords

  • HER2-expression
  • High-risk non-muscle invasive bladder cancer
  • intravesical instiliations
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary consent to participate in the study and signed the form.
  2. Male or female, age 18-75 years (including both).
  3. Histologic confirmed non-muscle invasive bladder urothelial carcinoma (NMIBC), and the risk group met the high-risk (including very high-risk) group.

    Note: High-risk NMIBC is a high-grade / G3 tumor meeting any of the following:

    a.Carcinoma in situ (CIS) b. T1 stage c. diameter>3cm d.Multiple tumors, or recurrent tumors.

  4. Absence of resectable disease(Ta and/or T1 disease) after transurethral resection (TURBT) procedures (residual CIS acceptable;
  5. The urologist assessed that radical surgery for bladder cancer was not suitable or the subject refused radical surgery for bladder cancer.
  6. Tumor tissue samples were detected by immunohistochemistry (IHC) to satisfy expression of 1+, 2+ or 3+.
  7. (ECOG) performance status of 0-1.
  8. Adequate heart, bone marrow, liver, kidney and coagulation function

Exclusion criteria

Exclusion Criteria:

    1. Invasive bladder cancer (T2 and above) and / or with regional lymph node and distant .

      1. Combined urothelial carcinoma outside the bladder (i. e., urethra, ureter or renal pelvis).
      1. Any other antitumor therapy received within 4 weeks before study administration, .

      4 Subjects plan to undergo major surgery during the study or within 4 weeks before the first dose.

      5, Known allergic to DV and its components or to any .

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Disitamab Vedotin Intravesical instiliations :Dose escalation cohort

    Participants will receive Disitamab Vedotin for injection Intravesical instiliations into the bladder for 1 hour, D1, once a week.

    Drug: Disitamab Vedotin for injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicity(DLT) (Phase I)

    Time frame: Approximately 21 days

  2. Incidence of Adverse event (Phase I)

    According to the NCI CTCAE V5.0, to evaluate safety including adverse event rate and adverse event grade

    Time frame: Approximately 1 years

  3. Recommended Phase II Dose(RP2D)

    Assessed based on the Incidence of DLT

    Time frame: Approximately 21 days

  4. Maximum Tolerated Dosage(MTD)

    Assessed based on the Incidence of DLT

    Time frame: Approximately 21 days

Secondary outcomes

  1. Disease-free survival (DFS) rates

    Disease-free survival (DFS) rates was defined as the time from the date of first study treatment to the time of the subject's first high-grade Ta, T1 of any grade, CIS lasting greater than or equal to 6 months, new carcinoma in situ (CIS), cystectomy, disease progression, or death from any cause

    Time frame: Up to approximately 2 years

  2. Duration of response (DOR)

    Defined as the time from the start of the first assessment of CR to the first assessment of high grade Ta, any grade of T1, new CIS, disease progression, cystectomy, or death from any cause

    Time frame: Up to approximately 2 years

  3. Disitamab Vedotin anti-drug antibody (ADA)

    The number and proportion of anti-drug antibody (ADA)-positive subjects were analyzed according to dose group and time point.

    Time frame: Up to approximately 2 years

  4. PK of enfortumab vedotin: Maximum concentration (Cmax)

    Cmax will be recorded from the PK blood samples collected.

    Time frame: Approximately 1 years

  5. PK of enfortumab vedotin: Trough concentration (Ctrough)

    Ctrough will be recorded from the PK blood samples collected.

    Time frame: Approximately 1 year

07

Study locations

2 of 6 sites recruiting
  • Sun Yat-sen Memorial Hospital,SunYat-sen University
    Guangzhou, Guangdong, China
    Recruiting
    • Tianxin Lin, Ph.D · Contact
  • Tongji Hospital
    Wuhan, Hubei, China
    Not yet recruiting
    • Shaogang Wang, M.D · Contact
  • Hunan Cancer hospital
    Changsha, Hunan, China
    Recruiting
    • Shusuan Jiang, M.D · Contact
  • The first affiliated hospital with nanjing medical universtity
    Nanjing, Jiangsu, China
    Not yet recruiting
    • qiang Lv, M.D · Contact
  • West China Hospital
    Chengdu, Sichuan, China
    Not yet recruiting
    • Peng Zhang, M.D · Contact
  • Tianjin Medical University Second Hospital
    Tianjin, Tianjin, China
    Not yet recruiting
    • Hailong Hu, M.D · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Mar 2029, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Apr 22, 2024
StartActual
Jun 14, 2024
Primary completionEst.
Mar 15, 2029
CompletionEst.
Dec 31, 2029
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06378242
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Apr 22, 2024
Start date
Jun 14, 2024
Primary completion
Mar 15, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jul 11, 2024

Study contacts

Hong Luo
Contact
hong.luo@remegen.com
+8610-58075763

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Disitamab vedotin

Start the discussion